Gynecologic Oncology
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Quality of end-of-life care for women with gynecologic malignancies in Ontario, Canada: A 14-year population-based retrospective analysis (132)
2022
-
Predictors of Minimally Invasive Surgery for Uterine and Cervix Cancer from 2000 – 2017 in Ontario, Canada
2020
-
Social determinants of health in uterine cancer patients in Ontario: Association with disease presentation and outcomes
2020
-
Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes
2020
-
Implementation of surgical treatment for early-stage cervical cancer by Kenyan gynecologists in western Kenya
2011
-
Treating vulvar cancer in the new millennium: Are patients receiving optimal care?
2008
-
A phase 2 trial of SNS-595 in women with platinum-refractory epithelial ovarian cancer
2008
-
Learned participation: Women's perceptions about treatment decision making in recurrent ovarian cancer
2008
-
Patterns of surgical care for gynecologic cancers in Ontario
2008
-
Incidence of endometrial cancer in BRCA mutation carriers..
189:148-155.
2024
-
Impact of timing of palliative care initiation on end-of-life quality metrics and health resource utilization (058).
176:S49-S49.
2023
-
Palliative care utilization across health sectors for patients with gynecologic malignancies in Ontario, Canada from 2006 to 2018.
175:169-175.
2023
-
Surgical margin status in relation to surgical approach in the management of early-stage cervical Cancer: A Canadian cervical Cancer collaborative (4C) study.
174:21-27.
2023
-
Disparities in the survival of endometrial cancer patients in a public healthcare system: A population-based cohort study.
167:532-539.
2022
-
Corrigendum to “Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes” [Gynecologic Oncology, Volume 157, Issue 1, April 2020, Pages 36–45].
167:399-399.
2022
-
Trends in quality indicators of end-of-life care for women with gynecologic malignancies in Ontario, Canada.
167:247-255.
2022
-
Comparison of outcomes between abdominal, minimally invasive and combined vaginal-laparoscopic hysterectomy in patients with stage IAI/IA2 cervical cancer: 4C (Canadian Cervical Cancer Collaborative) study.
166:230-235.
2022
-
Germline BRCA mutations are associated with an increased likelihood of secondary cytoreductive surgery in ovarian cancer patients (116).
166:S75-S76.
2022
-
The status of surgical margins in relation to the type of surgical approach in the management of early-stage cervical cancer: Canadian Cervical Cancer Collaborative (4C) study (533).
166:S261-S261.
2022
-
The five-factor modified frailty index predicts adverse postoperative and chemotherapy outcomes in gynecologic oncology.
166:154-161.
2022
-
The impact of preoperative imaging on wait times, surgical approach and overall survival in endometrioid endometrial cancers.
165:317-322.
2022
-
Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.
164:514-521.
2022
-
Addition of an Fc-IgG induces receptor clustering and increases the in vitro efficacy and in vivo anti-tumor properties of the thrombospondin-1 type I repeats (3TSR) in a mouse model of advanced stage ovarian cancer.
164:154-169.
2022
-
Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee.
161:502-507.
2021
-
The levonorgestrel intrauterine system for prevention of endometrial cancer in women with obesity: A cost-effectiveness study.
161:367-373.
2021
-
The use of imaging in endometrial cancer prior to potential surgery: Are guidelines being followed?.
161:361-366.
2021
-
A pneumococcal pneumonia and influenza vaccination quality improvement program for women receiving chemotherapy for gynecologic cancers at a major tertiary cancer Centre.
161:236-243.
2021
-
Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study.
161:221-227.
2021
-
Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation.
159:820-826.
2020
-
Disparities in surgical management of endometrial cancers in a public healthcare system: A question of equity.
159:387-393.
2020
-
Endometrial cancer presentation is associated with social determinants of health in a public healthcare system: A population-based cohort study.
158:130-136.
2020
-
Hyperglycemia promotes insulin-independent ovarian tumor growth.
149:361-370.
2018
-
Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
149:275-282.
2018
-
The role of adjuvant therapy in stage IA serous and clear cell uterine cancer: A multi-institutional pooled analysis.
149:283-290.
2018
-
FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper.
147:3-10.
2017
-
A systematic review of patient values, preferences and expectations for the treatment of recurrent ovarian cancer.
146:392-398.
2017
-
Nutrition interventions in patients with gynecological cancers requiring surgery.
145:192-199.
2017
-
Does a groin node dissection in vulvar cancer affect groin recurrence and overall survival?: Results from a population-based cohort study.
144:318-323.
2017
-
Cervical cancer screening in women over 65. PRO: Are we asking the right question?.
142:381-382.
2016
-
Patient, tumor, and health system factors affecting groin node dissection rates in vulvar carcinoma: A population-based cohort study.
139:465-470.
2015
-
Trends over time in the use of laparoscopic hysterectomy for the treatment of endometrial cancer.
138:536-541.
2015
-
A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A trial of the Princess Margaret, Chicago and California Phase II Consortia.
138:55-61.
2015
-
A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia.
137:216-222.
2015
-
Sentinel lymph node biopsy in vulvar cancer: Systematic review, meta-analysis and guideline recommendations.
137:351-361.
2015
-
Performance characteristics of a brief Family History Questionnaire to screen for Lynch syndrome in women with newly diagnosed endometrial cancer.
136:311-316.
2015
-
Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer.
135:184-189.
2014
-
A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: A study of the Princess Margaret, Chicago and California Consortia.
134:274-280.
2014
-
Trends in incidence and survival of women with invasive vulvar cancer in the United States and Canada: A population-based study.
134:314-318.
2014
-
Symptoms burden in subjects with cervical cancer and supportive care: Preliminary result from a developing country.
133:200-200.
2014
-
The association between cervical cancer screening and mortality from cervical cancer: A population based case–control study.
133:167-171.
2014
-
Non-radical surgery for small early-stage cervical cancer. Is it time?.
132:624-627.
2014
-
Systemic therapy in squamous cell carcinoma of the vulva: Current status and future directions.
132:780-789.
2014
-
Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer.
131:744-752.
2013
-
Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer.
131:315-320.
2013
-
Adjuvant treatment for endometrial cancer: Literature review and recommendations by the Comité de l'évolution des pratiques en oncologie (CEPO).
131:231-240.
2013
-
Surgery for early stage cervical cancer: How radical should it be?.
131:222-230.
2013
-
The wait time creep: Changes in the surgical wait time for women with uterine cancer in Ontario, Canada, during 2000–2009.
131:151-157.
2013
-
Risks and benefits of screening asymptomatic women for ovarian cancer: A systematic review and meta-analysis.
130:674-681.
2013
-
Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199).
130:269-274.
2013
-
How oncologists communicate information to women with recurrent ovarian cancer in the context of treatment decision making in the medical encounter.
130:e112.
2013
-
The wait time creep: Changes in the surgical wait time for women with uterine cancer in Ontario, Canada during 2000-2009.
130:e40-e41.
2013
-
International Gynecologic Cancer Society (IGCS 2012).
128:12-14.
2013
-
Sociodemographic factors associated with cervical cancer screening coverage and follow-up of high grade abnormal results in a population-based cohort.
128:95-100.
2013
-
Five-year trends in mortality indices among gynecological cancer patients in Canada.
127:620-624.
2012
-
Advancing fertility-sparing treatments in cervical cancer: Where is the limit?.
126:317-318.
2012
-
Preoperative identification of a suspicious adnexal mass: A systematic review and meta-analysis.
126:157-166.
2012
-
Surgical management of a suspicious adnexal mass: A systematic review.
126:149-156.
2012
-
A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia.
125:136-140.
2012
-
Combined methotrexate–dactinomycin: An effective therapy for low-risk gestational trophoblastic neoplasia.
124:553-557.
2012
-
Temporal trends in the relative survival among patients diagnosed with ovarian cancer in Canada 1992–2005: A population-based study.
123:192-195.
2011
-
The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation.
121:163-168.
2011
-
Conservative surgery for early stage cervical cancer: Who should we offer it to?.
119:173-174.
2010
-
A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149).
118:308-312.
2010
-
End of life care for women with gynecologic cancers.
118:196-201.
2010
-
Preferences for surveillance strategies for women treated for high-grade precancerous cervical lesions.
118:108-115.
2010
-
A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: A trial of the Chicago, PMH, and California Phase II Consortia.
117:37-40.
2010
-
Follow-up for women after treatment for cervical cancer: A systematic review.
114:528-535.
2009
-
Epithelial–stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer.
108:385-394.
2008
-
Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer.
108:317-325.
2008
-
UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: A study of the Princess Margaret Hospital Phase II consortium.
106:305-310.
2007
-
Use of systemic therapy in women with recurrent ovarian cancer—Development of a national clinical practice guideline.
106:181-192.
2007
-
Outcomes for systemic therapy in women with ovarian cancer.
103:554-558.
2006
-
A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: A National Cancer Institute of Canada Clinical Trials Group Study.
102:300-308.
2006
-
Adjuvant radiotherapy in women with stage I endometrial cancer: A systematic review.
102:361-368.
2006
-
Follow-up after primary therapy for endometrial cancer: A systematic review.
101:520-529.
2006
-
Invasive vulvar cancer in a woman with human immunodeficiency virus: Case report and review of the literature.
98:151-154.
2005
-
Systemic therapy for advanced uterine sarcoma: A systematic review of the literature.
97:624-637.
2005
-
Job satisfaction, stress, and burnout among Canadian gynecologic oncologists.
94:134-139.
2004
-
Optimal management for surgically Stage 1 serous cancer of the uterus.
92:240-246.
2004
-
Surgery as sole treatment for serous borderline tumors of the ovary with noninvasive implants.
90:407-412.
2003
-
Erratum to “Women’s perceptions about treatment decision making for ovarian cancer”.
90:232-232.
2003
-
Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116)☆.
89:129-133.
2003
-
Women’s perceptions about treatment decision making for ovarian cancer.
88:89-95.
2003
-
Outcomes in Surgery for Ovarian Cancer.
87:260-267.
2002
-
Malignant Ascites Fluid (MAF), Including Ovarian-Cancer-Associated MAF, Contains Angiostatin and Other Factor(s) Which Inhibit Angiogenesis.
86:279-287.
2002
-
A Comparison of Two Prophylactic Regimens for Hypersensitivity Reactions to Paclitaxel.
84:420-425.
2002
-
A Phase II Trial of JM-216 in Cervical Cancer: An NCIC CTG Study.
84:327-331.
2002
-
Weekly Intravenous Methotrexate with Folinic Acid for Nonmetastatic Gestational Trophoblastic Neoplasia.
82:367-370.
2001
-
Cutaneous Metastasis of Papillary Serous Uterine Cancer.
82:208-211.
2001
-
Is Uterine Papillary Serous Adenocarcinoma a Manifestation of the Hereditary Breast–Ovarian Cancer Syndrome?.
79:477-481.
2000
-
Endodermal Sinus Tumor in Pregnancy.
78:265-266.
2000
-
Reply.
78:266-266.
2000
-
Better Treatments That Cost More: The Dilemma.
78:1-2.
2000
-
Hysteroscopic Endometrial Resection and High-Dose-Rate Brachytherapy: Treatment of Endometrial Cancer in a Medically Compromised Patient.
75:149-151.
1999
-
An Endodermal Sinus Tumor Diagnosed in Pregnancy: Case Report and Review of the Literature.
72:123-127.
1999
-
Reply.
66:542-542.
1997
-
A Phase II Study of Leuprolide in Advanced/Recurrent Endometrial Cancer.
64:126-129.
1997
-
A Randomized Trial of Paracentesis plus Intraperitoneal Tumor Necrosis Factor-α versus Paracentesis Alone in Patients with Symptomatic Ascites from Recurrent Ovarian Carcinoma.
64:80-87.
1997
-
Patients’ Preferences for Therapy in Advanced Epithelial Ovarian Cancer: Development, Testing, and Application of a Bedside Decision Instrument.
62:329-335.
1996
-
Phase II Study to Evaluate the Toxicity and Efficacy of Concurrent Cisplatin and Radiation Therapy in the Treatment of Patients with Locally Advanced Squamous Cell Carcinoma of the Cervix.
58:38-41.
1995
-
Good Outcome Associated with a Standardized Treatment Protocol Using Selective Postoperative Radiation in Patients with Clinical Stage I Adenocarcinoma of the Endometrium.
57:138-144.
1995
-
High-Dose Methotrexate for Gestational Trophoblastic Disease.
54:282-287.
1994
-
Transforming Growth Factor α Localization and Role in Surface Epithelium of Normal Human Ovaries and in Ovarian Carcinoma Cells.
53:17-23.
1994
-
Detection of Human Papillomavirus Type 16 in Plasma Cells.
48:406-412.
1993
-
A rapid and simple method for the purification of tumor cells from ascitic fluid of ovarian carcinoma.
44:223-226.
1992
-
A phase I study of GM-CSF, cyclophosphamide (CP), and escalating doses of carboplatin (CBDCA) in chemotherapy-Naïve patients with ovarian cancer.
40:169-170.
1991
-
Effect of radiation and other cytotoxic agents on the growth of cells cultured from normal and tumor tissues from the female genital tract.
37:210-218.
1990
-
Recurrent and persistent squamous cell cervical carcinoma in women under age 35.
30:163-172.
1988
-
Adriamycin and cisplatin in the treatment of stage III and IV epithelial ovarian carcinoma.
29:208-221.
1988
-
A predictive index of cure versus no cure in advanced ovarian carcinoma patients—Replacement of second-look laparotomy as a diagnostic test.
27:269-278.
1987
-
Psychosexual rehabilitation and exenterative surgery.
6:236-242.
1978
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)